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Background & Aims: Hepatocyte-like cells, differentiated from
different stem cell sources, are considered to have a range of pos-
sible therapeutic applications, including drug discovery, meta-
bolic disease modelling, and cell transplantation. However, little
is known about how stem cells differentiate into mature and
functional hepatocytes.
Methods: Using transcriptomic screening, a transcription factor,
liver X receptor a (NR1H3), was identiﬁed as increased during
HepaRG cell hepatogenesis; this protein was also upregulated
during embryonic stem cell and induced pluripotent stem cell
differentiation.
Results: Overexpressing NR1H3 in human HepaRG cells pro-
moted hepatic maturation; the hepatocyte-like cells exhibited
various functions associated with mature hepatocytes, including
cytochrome P450 (CYP) enzyme activity, secretion of urea and
albumin, upregulation of hepatic-speciﬁc transcripts and an
increase in glycogen storage. Importantly, the NR1H3-derived
hepatocyte-like cells were able to rescue lethal fulminant hepatic
failure using a non-obese diabetic/severe combined immunodeﬁ-
cient mouse model.
Conclusions: In this study, we found that NR1H3 accelerates
hepatic differentiation through an HNF4a-dependent reciprocal
network. This contributes to hepatogenesis and is therapeutically
beneﬁcial to liver disease.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.AC
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CIntroduction
Liver development depends on a complex network, requiring sev-
eral growth factors, genetic homeostasis and cell-extracellular
matrix interactions [1]. Identifying the hepatogenesis-promoting
factors, favouring liver development, is thought to be essential for
liver regeneration and could improve hepatocyte transplantation
for end-stage liver disease [2]. Different sources of progenitor
cells have been investigated as potential sources for hepatic dif-
ferentiation, including human mesenchymal stem cells (MSCs)
[3,4], embryonic stem cells (ESCs) [5] and induced pluripotent
stem cells (iPSCs) [6], all of which hold the potential to differen-
tiate into hepatocyte-like cells. However, unstable hepatic func-
tion and atypical morphology have limited the usefulness of
present cell treatments. Thus, improved progenitor cells are
needed in order to carry out further studies of the treatments
of liver disease.
The human bipotent liver progenitor cell line HepaRG is an
alternative source of cells that is used for toxicity screening dur-
ing drug discovery [7,8], viral hepatitis research, hepatocyte dif-
ferentiation and transplantation testing [9]. This cell line has
several potential advantages. First, during differentiation,
HepaRG cells evolve from a homogeneous depolarized epithelial
phenotype showing no speciﬁc organization into a structurally
well-deﬁned and polarized monolayer that closely resembles
those formed by primary human hepatocytes in culture [10]. Sec-
ondly, these cells show long-term stability in terms of various
mature hepatocyte functions, including iron storage, cytochrome
P450 enzyme activities and albumin secretion [11]; Thirdly,
polarized hepatocyte-like cells differentiated from HepaRG cells
mimic mature primary human hepatocytes (PHHs) [12], as evi-
denced by the fact that they can support the in vitro infection
and replication of human hepatitis B virus (HBV) [13], a feature
that has not been observed in hepatocyte-like cells generated
from other stem cell systems. Thus, the HepaRG cell line has
become a promising in vitro model to determine not only the
basic regulation of hepatic cell fate but also the maturation into
hepatocytes.
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Table 1. Primers for RT-qPCR.
Primer Sequence
Albumin F: GGC ACA ATG AAG TGG GTA AC
R: AGG CAA TCA ACA CCA AGG
CK-18 F: CTA CAT CAA CAA CCT TAG GC
R: TCC ACA TCC TTC TTG ATG
HNF4A F: CCA AGT ACA TCC CAG CTT TC
R: TTG GCA TCT GGG TCA AAG
TDO2 F: GGA ACT ACC TGC ATT TGG
R: TCT CTG AAG TCA TTG AAG TCC
TAT F: ACT GTG TTT GGA AAC CTG CC
R: GCA GCC ACT TGT CAG AAT GA
CYP3A4 F: CCT TAC ATA TAC ACA CCC TTT G
R: GGT TGA AGA AGT CCT CCT AAG CT
CYP2B6 F: ATG GGG CAC TGA AAA AGA CTG A 
R: AGA GGC GGG GAC ACT GAA TGA C
NR1H3 F: GCT GCA AGT GGA ATT CAT CAA CC
R: ATA TGT GTG CTG CAG CCT CTC CA
ETV-1 F: GTG CCT GTA CAA TGT CAG TG
R: GGT AGC TGC TAT CTG GTA TG
HHEX F: GGT AAG CCT CTG CTG TGG TC 
R: TCT TCT CCA GCT CGA TGG TT 
XBP-1 F: ACA CGC TTG GGA ATG GAC AC
R: CCA TGG GAA GAT GTT CTG GG
GAPDH F: GAG TCC ACT GGC GTC TTC
R: GAC TGT GGT CAT GAG TCC TTC 
In order to screen the hepatic differentiation-inducing factors,
genome-wide studies have been conducted in other stem cell
systems to identify the regulatory circuitry involved in liver
development and hepatic cell speciﬁcation. For example, by
genome-wide chromatin immunoprecipitation (ChIP) combined
with promoter microarray analysis in liver and pancreas tissues,
the transcriptional regulators HNF1a, HNF4a and HNF6a were
found to occupy the promoters of various tissue-speciﬁc genes
and were also shown to be involved in the control of regulatory
circuits that are necessary for normal hepatocyte function [14].
In addition, HNF4a was found to be essential for the speciﬁcation
of hepatic progenitors from human pluripotent stem cells (iPSCs)
[15]. The homeobox transcription factor Prox1 (prospero-related
homeobox 1), an early speciﬁc marker during the development of
liver and pancreas from the foregut endoderm, is a co-regulator
of HNF4a and human liver receptor homolog-1 (hLRH-1)
[16,17]. Furthermore, combining genome-wide location and
microarray analysis has also helped to reveal the targets of
C/EBP beta (CCAAT enhancer-binding protein beta), a basic-
leucine zipper transcription factor; these targets are critical to
the regulation of numerous biological processes, including liver
development [18]. These and other ﬁndings have demonstrated
that a genomic approach is one of the key ways of screening for
important candidates that are likely to control hepatocyte differ-
entiation and liver development [19,20].
In this study we have identiﬁed the function of a novel tran-
scription factor, liver X receptor a (NR1H3), and show that it is
involved in the induction of the hepatic differentiation. This
was done by establishing the genomic proﬁle associated with
the development of functional hepatocyte-like cells from undif-
ferentiated HepaRG cells. Hepatocytes overexpressing NR1H3
showed signiﬁcant increases in several adult liver cell markers
and in the process gained a range of liver cell functions; more-
over, these cells were able to rescue hepatic failure when trans-
planted into CCl4-injured severe combined immunodeﬁciency
(SCID) mice. DAC
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HepaRG cell culture
HepaRG cells were cultured in William’s E medium (Gibco) supplemented with
10% FCS, 100 mM glutamine, 5 mg/ml insulin, 50 lM hydrocortisone hemisucci-
nate and 1% penicillin. The differentiated HepaRG cells were obtained as
described [10].
RNA isolation, reverse-transcription PCR (RT-PCR) and quantitative RT-PCR
RNA was extracted using the RNeasy kit (Qiagen). 1 lg RNA was reverse-tran-
scribed into cDNA using the Moloneymurine leukemia virus reverse-transcriptase
(M-MLV Reverse Transcriptase, Promega). For the reverse-transcription polymer-
ase chain reaction (RT-PCR), the following conditions were used: 94 C for 40 s,
56 C for 50 s, 72 C for 60 s for 30 cycles, after an initial denaturation at 94 C for
5 min. The primers used are listed in Table 1. Reverse-transcription quantitative
polymerase chain reaction (RT-qPCR) was performed using the StepOnePlus™
Real-Time PCR System (Applied Biosystems), and normalization to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used to quantify the messenger RNA
levels.
Periodic acid-Schiff (PAS) staining
HepaRG cells were ﬁxed in 4% formaldehyde for 30 min and then permeabilized
with 0.1% Triton X-100 for 10 min. The cells were next either treated or nottreated with diastase (Sigma–Aldrich) for 40 min, 37 C. The samples were then
oxidized in 1% periodic acid for 5 min, rinsed three times in deionized (d) H2O,
treated with Schiff’s reagent (Sigma–Aldrich) for 15 min in the dark, and rinsed
in dH2O for 5 min. Finally, cells were visualized by light microscopy.
Measurement of cytochrome P450 enzyme activity
CYP3A4 activity was measured using a P450-Glo Assays kit (Promega) according
the manufacturer’s instructions. Brieﬂy, cells were washed with phosphate-
buffered saline (PBS), which was then replaced with fresh medium containing
luminogenic CYP3A4 substrate luciferin-PFBE, followed by a 3 h incubation at
37 C. To determine CYP P450 enzyme activity, 50 ll of medium was transferred
and 50 ll luciferin detection reagent was added to initiate the luminescent reac-
tion for 30 min. The luminescence of the mixture was then read using an Inﬁnite
M1000 (TECAN Group Ltd.) luminometer. Cytochrome activity was stated as
relative light units (RLU)/106 cells/ml.
Gene expression microarray
Total RNA was isolated from HepaRG cells by RNeasy Mini kit (Qiagen). The
expression proﬁles were performed by the National Research Progress for Geno-
mic Medicine Microarray and Gene expression analysis Core Facility, National
Yang-Ming University, Taiwan. Gene expression analysis was done as described
in our previous publication [21].
Animal model and HepaRG cell transplantation
Five-week-old NOD-SCID mice were injected intrasplenically with 2.5  107 via-
ble NR1H3-derived hepatocytes and HepaRG cells per kilogram body weight 24 h
after administration of carbon tetrachloride (CCl4), the procedure was modiﬁed
based on previously publications [22,23]. Primary human hepatocytes were
purchased from Life Technologies (HEP10, Gibco) and cultured according the
manufacturer’s instructions.
Urea production
Urea production by HepaRG cells was determined by the Urea Assay kit
(BioVision) according to the manufacturer’s instructions. Brieﬂy, 25 ll of culture
medium was directly added into 96-well plates and incubated with 50 ll of assay
buffer for 1 h at 37 C while protected from light. The amount of urea present was
measured at OD 570 nm using a microplate reader.
Histopathology and immunochemical analysis
Samples were collected 8 days after transplantation. Organs were ﬁxed with 4%
paraformaldehyde and prepared in parafﬁn-embedded blocks for sectioning at
4-micrometer thickness. The sections were deparaﬁnized, rehydrated and epitope
retrieval was performed in Trilogy™ solution (Cell Marque) by autoclaving for
10 min. The sections were then incubated with anti-human NR1H3 antibody
(5 lg/ml, Abnova), anti-human albumin antibody (2.5 lg/ml, Abcam Inc.) and
anti-cytokeratin 19 antibody (1 lg/ml, Mybiosource Inc.) at 4 C overnight,
followed by staining with goat antibodies against rabbit IgG (Dako), or a goat
anti-mouse IgG antibody (Dako) for 40 min at room temperature.
Western blotting
After HepaRG cell lysis, 50 lg total protein was resolved by 10% SDS polyacryl-
amide gel electrophoresis, transferred onto NC membrane and analysed with
antibodies against HNF4A (ABGENT) and NR1H3 (Abnova).
Human albumin assay
Human albumin production by the HepaRG cells was determined by the human
serum albumin EIA Kit (ACE) according to the manufacturer’s instructions. Brieﬂy,
50 ll mouse plasma was directly added into 96-well plates and incubated with
Immunoassay buffer A for 1 h at 37 C and the AChE Tracer, EIA monoclonal anti-
body for 2 h at room temperature while protected from light. The amount of
human albumin present was measured at OD 420 nm using a microplate reader.MAC
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 ResultsGene expression proﬁles that reﬂect the differentiation of HepaRG
progenitor cells into hepatocyte-like cells
A protocol, which is described in the Materials and methods sec-
tion (Fig. 1A), was used to induce the differentiation of human
HepaRG progenitor cells in a synchronous fashion; the differenti-
ation recapitulated the steps known to occur during hepatogene-
sis. Bipotent progenitor HepaRG cells, plated at 2.6  104 cells/
cm2 in the presence of insulin and corticosteroids, ﬁrst gave rise
to undifferentiated cells that actively proliferated for 7 days.
These cells then committed into the hepatocyte and biliary differ-
entiation pathways early after reaching conﬂuence at day 14
(Fig. 1B, Panel [i]). The cells then organized themselves in either
ﬂat clear epithelial cells or cords of granular polygonal cells
(Fig. 1B, Panel [ii]). At day 14, dimethyl sulfoxide (DMSO) was
added into the culture medium, and maximum cell differentia-
tion was reached after 2-week DMSO exposure (Fig. 1B, Panel
[iii]). Hepatocyte-like cells that had exhibited a phenotype close
to that of human hepatocytes, namely where periodic acid-Schiff
(PAS) staining showed glycogen storage function, were identiﬁed
as differentiated hepatocyte-like cells (Fig. 1B, Panels [iv], [v], and
[vi], magenta staining shows presence of glycogen).
To determine whether our HepaRG-derived hepatocyte-like
cells display the mature characteristics of a hepatic lineage, we
examined in these cells the gene expression levels of various
human hepatocyte markers, namely albumin, cytochrome P450
3A4 (CYP3A4), cytochrome P450 2B6 (CYP2B6) and cytokeratinAN
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18 (KRT18) by reverse-transcription quantitative polymerase
chain reaction (RT-qPCR); the results were normalized against
undifferentiated HepaRG cells. As can be seen in Fig. 1C, all of
these genes were expressed at signiﬁcantly higher levels in the
HepaRG-derived cells. To assess the functional status of
HepaRG-derived hepatocyte-like cells, we determined the urea
production and metabolic capacities of the differentiated cells.
Urea production signiﬁcantly increased during differentiation
(Fig. 1D). In addition, cytochrome P450 enzyme 3A4 (CYP450)
activity, which is one of the most important enzymes involved
in the metabolism of xenobiotics in the liver [24], was also
elevated during differentiation (Fig. 1E).
Gene expression microarray analysis of the hepatogenesis of
HepaRG cells at 3 stages (undifferentiated, committed, and differ-
entiated) was carried out. The principal component analysis (PCA)
of the committed and differentiated HepaRG cells (red and blue
spots, respectively), based on genes differentiating ESCs and pri-
mary hepatocytes (pFDR q <105) compared to the iPSC-derived
or ESC-derived hepatic cells (magenta and orange spots, respec-
tively), showed that the HepaRG-derived hepatocyte-like cells
were distinct from the original HepaRG cells (brown spots) and
were much closer to primary hepatocytes (PH) (purple spots)
and liver tissue (green spots) (Fig. 1F). Our differentiated cells
were found to be closest to primary hepatocytes. To ensure that
the developmental signatures were not just speciﬁc to hepatocyte
differentiation from HepaRG cells, genes that were differentially
expressed between ESC and ESC-derived hepatocytes [25] were
ﬁltered and overlapped with the 1086 probe sets (Supplementary
Fig. 1A). The results showed that a total of 895 probe sets were
conserved between both HepaRG and ESC hepatogenesis (Supple-
mentary Fig. 1B). These ﬁndings indicate that hepatocyte-like cells
derived fromHepaRG bipotent progenitor cells possess the largest
number of primary hepatocyte features and functions and that
studying the HepaRG differentiation process should help us to
identify mechanisms that are critical to the hepatogenesis
process.
NR1H3/LXRa is required for the hepatic differentiation of HepaRG
cells
One of the major goals of this study was to identify hepatogene-
sis-determining factors. In this context, we favoured nuclear
transcription factors (TFs) since TFs are critical cell fate determi-
nants [26,27]. Six TFs, namely HHEX, ETV1, XBP-1, MLXIPL, NR1H3
and HNF4A, were found to be present at increased levels during
hepatogenesis in both HepaRG progenitor cells and pluripotent
stem cells (Fig. 1G). We conﬁrmed that there was reliably expres-
sion of ﬁve of these TFs during the hepatic differentiation of
HepaRG cells (Fig. 1H). The exception was MLXIPL where we
failed to obtain the expression construct.
To evaluate the possible functions of these TFs, we determined
the hepatogenesis-promoting ability of HepaRG cells over-
expressing ﬁve of these TFs without DMSO treatment. The results
revealed that the expression level of various hepatic genes were
signiﬁcantly higher in hepatocyte-like cells expressing NR1H3
and HNF4A (Fig. 2A and B); this was in contrast to the other three
TFs, which showed no ability to promote the efﬁciency of hepato-
genesis (Supplementary Fig. 1C).
NR1H3 (also known as liver X receptor a or LXRa) belongs to a
hormone receptor superfamily of ligand-activated transcription
factors [28] that regulate lipid metabolism [29,30] and the
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inﬂammation response [31]. The involvement of NR1H3 in
human ESC or iPSC hepatic differentiation is supported by the
genomic data of Si-Tayeb et al. [25], which are presented in Sup-
plementary Fig. 2. HNF4A is known to directly control the expres-
sion of many hepatic genes and is also crucial for the
maintenance of a network of transcription factors that is essential
for normal hepatocyte function [32], serving as a positive control
in this study.
We determined the functional status of NR1H3-derived hepa-
tocyte cells, which exhibited higher glycogen storage ability than
parental HepaRG cells and the level was similar to that of HNF4A-
overexpressing cells (Fig. 2C, magenta staining shows presence of
glycogen). These cells also have a signiﬁcantly higher urea pro-
duction (Fig. 2D) and cytochrome P450 3A4 enzyme activity
(Fig. 2E) compared to empty lentivirus vector controls. Further-
more, their activities were also increased during differentiation.
These ﬁndings suggest that NR1H3, just like HNF4A, is able to
improve the efﬁciency of HepaRG cells to differentiate into func-
tional hepatocytes.
To further conﬁrm the critical role of NR1H3 in the formation
of hepatocyte-like cells, we generated shRNAs that were designed
to target NR1H3 or HNF4A using lentiviral transduction. In con-
trast to the differentiation of the control cells, the NR1H3- or
HNF4A-depleted HepaRG cells were found to have severely
diminished levels of the relevant hepatic mRNA (Supplementary
Fig. 3A and B). Furthermore, glycogen storage, urea production, as
well as cytochrome P450 enzyme activities were all signiﬁcantly
lower in HepaRG cells that lacked NR1H3 or HNF4A expression
(Supplementary Fig. 3C–E); this supports the hypothesis that
NR1H3 is a newly discovered crucial regulator involved in
stem/progenitor cell hepatic differentiation.
Reciprocal regulation between NR1H3 and HNF4
To provide more mechanistic insights into how NR1H3 is able to
regulate stem cell hepatogenesis, we performed oligonucleotide
array analysis on HepaRG cells overexpressing NR1H3 and
HNF4A; these were compared to empty lentiviral vector control
cells after completing the ﬁrst 7 days of differentiation without
DMSO treatment (Fig. 3A). The aim was to provide an unbiased
global transcriptome measurement that compared differentiated
hepatocyte-like cells with NR1H3 and HNF4A overexpressing
hepatocyte cells. The hepatic character was deﬁned using a mul-
tidimensional scaling (MDS) plot and showed that NR1H3-over-
expressing HepaRG cells were closer to differentiated
hepatocyte-like cells than 7-day control differentiation and com-
mitted HepaRG cells (Fig. 3B). It should be noted that the tran-
scriptome of NR1H3-overexpressing HepaRG cells showedAC
C
Fig. 1. Characterization and identiﬁcation of mRNA involved in the differentiation
procedure. (B) Images showing the morphological changes in HepaRG cells that oc
undifferentiated HepaRG cells at 14 days after seeding at low density. Panel (ii): Hepa
cultured and maintained for 15 days in the presence of DMSO. Panels (iv–vi): Periodic ac
(C) mRNA expression the hepatocyte markers albumin, cytochrome P450 3A4 (CYP3A4), c
culture; Gene expressions were normalized to glyceraldehyde 3-phosphate dehydrogenas
cytochrome P450 enzyme activity. (F) Principal component analysis showing transcriptom
blue spots, respectively), iPSC-derived or ESC-derived hepatic cells (magenta and orange
primary hepatocyte cells (purple spots, PH) and liver tissue (green spots, Liver) (G) Tw
expression; blue, low expression). Six up-regulated transcription factors were identiﬁed
were analysed by qPCR.AN
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88.9% (965 probe sets of 1086 probe sets of the hepatogenesis
in HepaRG cells at 3 stages) similarity to the transcriptome of
HNF4A-overexpressing cells (Fig. 3C), indicating these two tran-
scription factors have similar hepatogenesis-inducing functions.
Genes activated or repressed by both NR1H3 and HNF4A are pre-
sented in Supplementary Fig. 4A using two heat maps.
Surprisingly, we found that overexpression or knockdown of
NR1H3 in HepaRG progenitor cells was able to induce the expres-
sion or suppression of the endogenous HNF4A gene, respectively
(Fig. 3D). The NR1H3 promoter is known to be occupied by HNF4A
in both hepatocytes and pancreatic islets cells [14]. Furthermore,
hepatocyte-like cells derived from HNF4A-knockdown ESCs
expressed signiﬁcantly less NR1H3 mRNAs than control ESC-
derived cells when HNF4A expression is targeted by shRNAs in
human H9 pluripotent ESCs (Supplementary Fig. 4B). The latter
ﬁnding was discovered by analysing the transcriptomes of both
control ESCs and HNF4A-knockdown ESCs that had completed
the hepatic differentiation protocol (Supplementary Fig. 4B)
[15]. Based on the above ﬁndings, we performed reporter assays
to investigate whether the HNF4A promoter can be targeted by
NR1H3 as well as to identify any critical binding sites for
NR1H3 within the HNF4A promoter. This was done by creating
reporter constructs that contained different lengths of the HNF4A
promoter (Fig. 3E, left panel). An increase in HNF4A promoter
activity was observed after transient transfection of the
P2/-2200 reporter construct with NR1H3 (Fig. 3E). Deleting the
region between 2200 and 1500 base pairs of the HNF4A pro-
moter diminished HNF4A promoter activity by 17%, while further
deletion of a region between 1000 to 500 base pairs totally
abolished HNF4A promoter activity (Fig. 3E, right panel). These
results demonstrate that NR1H3 and HNF4A form a reciprocal
regulation circuit that is involved in promoting stem cell hepato-
genesis (Fig. 3F).
NR1H3-derived hepatocyte-like cells can rescue lethal fulminant
hepatic failure
To assess the therapeutic potential of NR1H3-derived hepato-
cytes, a model of lethal fulminant hepatic failure caused by
CCl4 in NOD-SCID mice was used. A dose of CCl4 at 0.35 ml/kg
body weight resulted in lethality in all animals 2 weeks after
administration of CCl4. Transplantation of 2.5  107 viable
HepaRG cell (empty lentivirus vector control) per kilogram body
weight failed to rescue recipient animals from hepatic failure (0
of 8 mice survived). However, when the mice received NR1H3-
derived hepatocytes, 87% of the recipient animals were rescued
from lethal liver damaged (7 out of 8 mice survived) (Fig. 4A).
Histopathologic analysis indicated the presence of massiveof HepaRG cells into hepatocyte-like cells. (A) Schematic of the differentiation
cur as they differentiate into hepatocyte-like cells. Panel (i): Morphology of
RG cells cultured for 20 days without DMSO induction. Panel (iii): HepaRG cells
id-Schiff staining showing the glycogen storage in the differentiated HepaRG cells.
ytochrome P450 2B6 (CYP2B6) and cytokeratin 18 (KRT18) after different times in
e (GAPDH). (D) Differentiated HepaRG cells are able to secrete urea and (E) exhibit
e proﬁle similarity between committed and differentiated HepaRG cells (red and
spots, iPSC_hepa and ESC_hepa, respectively), original HepaRG cells (brown spots),
o heat maps showing mRNA expression levels at different time points (red, high
during HepaRG cells differentiation. (H) Selected candidate transcription factors
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Fig. 2. NR1H3 is sufﬁcient for differentiation of hepatocyte-like cells from HepaRG cells. (A) Schematic of the differentiation procedure by virus infection.
Immunoblotting and RT-qPCR analysis of NR1H3 and HNF4A protein and mRNA levels during differentiation of HepaRG cells into hepatocyte-like cells. (B) RT-qPCR analysis
shows high mRNA levels for mature hepatocyte markers throughout the differentiation when NR1H3 and HNF4A is overexpressed in HepaRG cells. After 14 days
overexpression, the NR1H3-derived hepatocyte-like cells exhibited liver markers similar to primary human hepatocytes (PHH). (C) Periodic acid-Schiff staining shows the
glycogen storage of NR1H3 and HNF4A-derived hepatocyte-like cells. (D) NR1H3 and HNF4A over-expression, increased urea production and (E) cytochrome P450 enzyme
activity.necrosis in the livers of the untreated control mice. This contrasted
with the rescue of hepatic necrosis when the mice received NR1H3-
derived hepatocytes; however, such rescue was absent when the
mice received vector control HepaRG cells (Fig. 4B).To investigate whether the transplanted cells were engrafted
within the livers of the recipient mice, a human NR1H3 antibody
was used to detect the presence of human NR1H3-derived hepa-
tocytes in mouse liver. In addition, the hepatic functions of the
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targeting different regions of the promoter, namely the 500  1000 bp. (F) Proposed model of hepatic differentiation regulated by NR1H3.ACdetected NR1H3-derived hepatocytes were identiﬁed by immu-nohistochemistry, namely the detection of human albuminexpression in mouse livers (Fig. 4C and D). These ﬁndings showthat human NR1H3-derived hepatocytes had become engrafted
in the recipient’s liver parenchyma and that these cells were able
to successfully rescue the mice from hepatic failure. Consistently,
biochemical tests showed the improved recovery of liver func-
tions by transplantation of NR1H3-derived hepatocytes, which
was similar to primary human hepatocytes (Supplementary
Fig. 5 and Table 2).Discussion
Since the HepaRG cell line was ﬁrst described in 2002, many
reports [33,34] have appeared that have described its unique fea-
tures. These include the ability to differentiate towards both
hepatocyte-like and biliary-like cells and the ability to stably
express a range of important hepatic functions. In this study,
we have demonstrated that the transcription factor NR1H3 con-
tributes to the differentiation of functional hepatocytes from
HepaRG cells and it does this by inducing HNF4A, a protein that
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Fig. 4. NR1H3-derived hepatocyte-like cells can rescue CCl4-induced lethal fulminant hepatic failure. (A) Survival curves of NOD-SCID mice (n = 8 in each group) that
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trolling the development of liver architecture. Overexpression of
NR1H3 in HepaRG cells led to the efﬁcient differentiation of
HepaRG cells into hepatocyte-like cells that exhibit metabolic
enzyme activity, mature hepatic markers, urea secretion and gly-
cogen storage ability. Importantly, NR1H3-derived hepatocyte
cells were found to rescue lethal fulminant hepatic failure. Ourresults describe a novel mechanism that is able to successfully
and efﬁciently generate functional hepatocyte-like cells that will
be useful for studying liver development and regeneration.
The effect of NR1H3 on hepatocyte generation has not been
identiﬁed previously. Other studies have focused on the choles-
terol homeostasis and inﬂammation related activities of NR1H3,
which is also known as liver X receptor a (LXRa), in the liver.
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Table 2. Liver function tests of NOD-SCID mice that were administered
0.35 ml/kg CCl4 and underwent transplantation with NR1H3-derived HepaRG
cells, DMSO-induced differentiated HepaRG cells, vector control HepaRG cells
or primary human hepatocytes.
Serum glutamyl 
pyruvic 
transaminase (IU/L)
Human 
albumin/total 
albumin (%)
Normal NOD-SCID 20 ± 6.55 n.d.
Post-CCl4 day 1
4088 ± 405.4 n.d.
Post-CCl4 day 3
IS-vector control 607 ± 31.28 3.2%
IS-PHH 107 ± 10.338 14.8%
IS-HepaRG-NR1H3 170 ± 15.79 11.1%
IS-HepaRG-DIFF 193 ± 17.017 12.07%
Post-CCl4 day 5
IS-vector control 572 ± 36 3.08%
IS-PHH 72 ± 7.17 17.1%
IS-HepaRG-NR1H3 120 ± 10.1 14.53%
IS-HepaRG-DIFF 121 ± 7.13 12.05%
Post-CCl4 day 7
Vector control 590 ± 44.43 2.5%
IS-PHH 56 ± 2.9 15.65%
IS-HepaRG-NR1H3 89 ± 8.85 12.59%
IS-HepaRG-DIFF 78 ± 6.28 10.95%
Post-CCl4 day 14
IS-vector control n.d. n.d.
IS-PHH 33 ± 1.5 13.72%
IS-HepaRG-NR1H3 55 ± 5.46 14.02%
IS-HepaRG-DIFF 70 ± 3.02 13.6%
Post-CCl4 day 30
IS-vector control n.d. n.d.
IS-PHH 29 ± 5.82 8.36%
IS-HepaRG-NR1H3 49 ± 2.01 7.78%
IS-HepaRG-DIFF 45 ± 5.32 6.19%
Data are presented as mean ± SD of 3 determinations.
IS, intrasplenic transplantation; ND, not done; DIFF, DMSO-induced differentiated
HepaRG cells; PHH, primary human hepatocyte.AC
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PTNR1H3 is critical for the peroxisome proliferator-activated recep-tor (PPAR) pathways, and there are clues that seem to support thehypothesis that the PPAR pathways play a role in hepatogenesis:
PPAR-beta could facilitate the maturation of hepatic-like tissue
derived from mouse embryonic stem cells and this was accompa-
nied by mitochondriogenesis and membrane potential retention
[35]. In addition, PPAR-alpha induced hepatic differentiation of
rat oval cells, which act as bipotential progenitors for the two
main hepatic lineages [36]. This is similar to the situation in
HepaRG cells as rat oval cells are considered to be closely related
to liver stem cells [36]. Inhibition of adult oval cell growth and
viability has been noticed in the presence of a PPAR gamma ago-
nist [37]. PPAR pathways as well as NR1H3, may have an impor-
tant role in cellular energy metabolism during hepatogenesis.
Liver regeneration occurs both by replication of differentiated
hepatocytes and through activation of a ductular reaction [38].
NR1H3-derived hepatocytes may enhance liver regeneration by
several potential mechanisms: ﬁrst, cytokines secreted by the
implanted cells might improve liver regeneration via a paracrineAN
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IP
T
mechanism [39–41]. We found seven secreted factors are
induced by NR1H3 in HepaRG cells, namely C5, CCL14/CCL15,
CXCL2, IGF-1, MST-1, TNFSF10 and TSLP (Supplementary
Fig. 6A). Among them, IGF-1 [42] and MST-1 [43] have been
linked to liver regeneration and hepatic differentiation, and their
increased levels in NR1H3-overexpressing HepaRG cells could be
veriﬁed by RT-qPCR (Supplementary Fig. 6B). Secondly, trans-
planted cells may replace damaged tissues. We found that
NR1H3 increases the expression levels of hepatic and prolifera-
tion-related factors such as HNF4A (Supplementary Figs. 8 and
9) [19], FOXA2 [44], PPAR gamma [45], HNF1, CEBP and Ki67
[46] (Supplementary Fig. 7). Together these factors may acceler-
ate the proliferation of hepatocyte-like cells and help liver repair.
Thirdly, since part of our NR1H3-derived cells express CK-19
(cholangiocytes marker) in vivo (Supplementary Fig. 10), a ductu-
lar reaction may also occur in response to acute severe and
chronic liver injury [47,48].
HepaRG cells have been used in a variety of studies, including
those involving liver toxicity [49,50], hepatitis viruses infection
[51], human hepatic diseases and differentiation. The currently
used differentiation procedure takes 4 weeks in DMSO-treated
medium. In contrast, our results indicate that it is feasible to
obtain functional hepatocyte-like cells within 7 days by over-
expressing NR1H3 in HepaRG cells without DMSO treatment.
Kotokorpi et al. [52] found that one LXR endogenous ligand,
GW3965, is able to reduce the secretion of bile acids and increase
lipid storage. Other synthetic agonists, including T0901317 and
N,N-dimethyl-3b-hydroxycholenamide, have also been used to
identify the functions of NR1H3 [53]. In such circumstances, since
NR1H3 is involved in hepatic development, it is possible that the
addition of NR1H3 agonists to the HepaRG culture mediummight
be an alternative approach to accelerate HepaRG cell hepatocyte
differentiation in vitro.
Moreover, analysis of the gene expression proﬁles of
ESC-derived and iPSC-derived hepatic progenies has shown that
NR1H3, as well as HNF4A, are also highly expressed in hepato-
cyte-like cells derived from these pluripotent stem cells. This
indicates that the activation of NR1H3 is universal in stem/pro-
genitor cell hepatogenesis. The addition of NR1H3 agonists into
differentiation cocktails might also be beneﬁcial for the genera-
tion of functional hepatocyte-like cells from other stem cell
resources and for further studies of hepatocyte transplantation
in end-stage liver disease. Finally, it is also possible to accelerate
liver regeneration in vivo by liver-speciﬁc target delivery of
NR1H3 agonists, such as to package agonists into liver-speciﬁc
vehicles [54,55].
In conclusion, we have identiﬁed a novel hepatogenesis regu-
lator, NR1H3. This transcription factor activates and promotes
hepatic differentiation by inducing HNF4A expression (Fig. 3F).
We have also established the expression proﬁles that occur dur-
ing HepaRG differentiation and these ﬁndings should help
researchers to obtain a better understanding of the hepatic devel-
opment. Furthermore, NR1H3-derived hepatocytes may serve as
an alternative source of cells for further studies on liver develop-
ment and regeneration.Financial support
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